- Home
- ACIU vs GAMB Comparison
ACIU vs GAMB Comparison
Compare ACIU & GAMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- GAMB
- Stock Information
- Founded
- ACIU 2003
- GAMB 2006
- Country
- ACIU Switzerland
- GAMB Jersey
- Employees
- ACIU N/A
- GAMB N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- GAMB Services-Misc. Amusement & Recreation
- Sector
- ACIU Health Care
- GAMB Consumer Discretionary
- Exchange
- ACIU Nasdaq
- GAMB Nasdaq
- Market Cap
- ACIU 305.7M
- GAMB 338.0M
- IPO Year
- ACIU 2016
- GAMB 2021
- Fundamental
- Price
- ACIU $3.38
- GAMB $13.04
- Analyst Decision
- ACIU Strong Buy
- GAMB Strong Buy
- Analyst Count
- ACIU 2
- GAMB 5
- Target Price
- ACIU $12.00
- GAMB $15.00
- AVG Volume (30 Days)
- ACIU 132.6K
- GAMB 270.0K
- Earning Date
- ACIU 11-05-2024
- GAMB 11-14-2024
- Dividend Yield
- ACIU N/A
- GAMB N/A
- EPS Growth
- ACIU N/A
- GAMB 306.73
- EPS
- ACIU N/A
- GAMB 0.78
- Revenue
- ACIU $48,505,404.00
- GAMB $124,404,000.00
- Revenue This Year
- ACIU N/A
- GAMB $17.13
- Revenue Next Year
- ACIU $938.44
- GAMB $11.30
- P/E Ratio
- ACIU N/A
- GAMB $16.81
- Revenue Growth
- ACIU 4097200.00
- GAMB 27.63
- 52 Week Low
- ACIU $2.25
- GAMB $7.52
- 52 Week High
- ACIU $5.14
- GAMB $13.19
- Technical
- Relative Strength Index (RSI)
- ACIU 55.80
- GAMB 78.67
- Support Level
- ACIU $3.16
- GAMB $11.84
- Resistance Level
- ACIU $3.41
- GAMB $13.19
- Average True Range (ATR)
- ACIU 0.24
- GAMB 0.58
- MACD
- ACIU 0.03
- GAMB 0.30
- Stochastic Oscillator
- ACIU 43.18
- GAMB 95.97
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About GAMB Gambling.com Group Limited
Gambling.com Group Ltd is a multi-award-winning performance marketing company and a provider of digital marketing services in the online gambling industry. Its principal focus is on online casino and online sports betting and the fantasy sports industry. It generates revenue by referring online gamblers to online gambling operators.